Veracyte, Inc.
VCYT
株式のランク
#4318
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
株価
$45.86
時価総額
$3.69B
変化（1日）
2.39%
変化（1年）
27.04%
国
US
取引 Veracyte, Inc. (VCYT)
カテゴリー
Healthcare
Veracyte, Inc.（VCYT）の収益
Jun 2026 時点の収益 TTM: $561.90M
Veracyte, Inc. の最新の財務報告によると、現在の収益 (TTM) は $561.90M です。2023 年には $361.05M の収益があり、これは 2022 年の $296.54M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Veracyte, Inc. の収益履歴（2011 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $561.90M | 26.05% |
| 2024 | $445.76M | 23.46% |
| 2023 | $361.05M | 21.76% |
| 2022 | $296.54M | 35.09% |
| 2021 | $219.51M | 86.85% |
| 2020 | $117.48M | -2.40% |
| 2019 | $120.37M | 30.82% |
| 2018 | $92.01M | 27.87% |
| 2017 | $71.95M | 10.55% |
| 2016 | $65.09M | 31.48% |
| 2015 | $49.50M | 29.62% |
| 2014 | $38.19M | 74.51% |
| 2013 | $21.88M | 88.20% |
| 2012 | $11.63M | 339.62% |
| 2011 | $2.65M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $46.34B | 8,146.31% |
US
|
|
| $25.11B | 4,368.23% |
US
|
|
| $2.71B | 381.77% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 1,211.98% |
US
|
